Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Gains from Investment Securities (2016 - 2025)

Palisade Bio has reported Gains from Investment Securities over the past 13 years, most recently at $89400.0 for Q3 2025.

  • Quarterly Gains from Investment Securities changed N/A to $89400.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$355000.0 through Dec 2025, up 5.11% year-over-year, with the annual reading at $116600.0 for FY2025, 130.1% up from the prior year.
  • Gains from Investment Securities was $89400.0 for Q3 2025 at Palisade Bio, roughly flat from $89400.0 in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $799562.0 in Q3 2021 and troughed at -$355000.0 in Q4 2022.
  • The 4-year median for Gains from Investment Securities is $61590.0 (2021), against an average of $94463.4.
  • Year-over-year, Gains from Investment Securities plummeted 55.6% in 2021 and then crashed 1009.14% in 2022.
  • A 4-year view of Gains from Investment Securities shows it stood at $39048.0 in 2021, then crashed by 1009.14% to -$355000.0 in 2022, then surged by 101.29% to $4576.0 in 2023, then soared by 1853.67% to $89400.0 in 2025.
  • Per Business Quant, the three most recent readings for PALI's Gains from Investment Securities are $89400.0 (Q3 2025), $89400.0 (Q2 2025), and $4576.0 (Q3 2023).